Identification of EBV transforming genes by recombinant EBV technology

Seminars in Cancer Biology

Volumn 11, Issue 6, 2001, Pages 407-414

  Izumi, Kenneth M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Genetics; Herpes virus; Lymphocyte; Recombinant; Transformation

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; GENE PRODUCT; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

B LYMPHOCYTE; BACTERIAL ARTIFICIAL CHROMOSOME; CELL GROWTH; CELL TRANSFORMATION; EPSTEIN BARR VIRUS; GENE FUNCTION; GENETIC ANALYSIS; GENETIC RECOMBINATION; HUMAN; NONHUMAN; REVIEW; VIRAL GENETICS; VIRION; VIRUS CARCINOGENESIS; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0035197919     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0407     Document Type: Article

References (57)

1. Epstein-Barr virus and its replication
2. Epstein-Barr virus
3. Effect of the diterpene ester TPA on Epstein-Barr virus antigen and DNA synthesis in producer and nonproducer cell lines
4. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate
5. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency
6. Epstein-Barr virus infection of human gastric carcinoma cells: Implication of the existence of a new virus receptor different from CD21
7. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells
8. Epstein-Barr virus (EBV) recombinants: Use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells
9. BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication
10. Targeted gene disruption in Epstein-Barr virus
11. Marker rescue of a transformation-negative Epstein-Barr virus recombinant from an infected Burkitt lymphoma cell line: A method useful for analysis of genes essential for transformation
12. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes
13. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation
14. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection and interference
15. EBNA2 transactivation and transformation
16. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23
17. Effect of the EBNA-2 gene on the surface antigen phenotype of transfected EBV-negative B-lymphoma lines
18. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization
19. EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus
20. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator
21. Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTC-binding protein is essential for B lymphocyte growth transformation by EBV
22. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation
23. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation
24. Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: A role for the WIW2 repeat domain
25. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro
26. BHRF1 of Epstein-Barr virus, which is homologous to human proto-oncogene bc12, is not essential for transformation of B cells or for virus replication in vitro
27. Epstein-Barr virus recombinants with specifically mutated BCRF1 genes
28. Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI
29. Activation of the interferon-inducible (2′-5′) oligoadenylate synthetase by the Epstein-Barr virus RNA, EBER-1
30. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata
31. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death
32. Expression of interleukin-10 activity, by Epstein-Barr virus protein BCRF1
33. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro
34. Second-site homologous recombination in Epstein-Barr virus: Insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection
35. The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential
36. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation
37. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation
38. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity
39. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
40. LMP1 structure and signal transduction
41. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family
42. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB
43. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosisfactor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation
44. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation
45. Intracellular forms of human NOTCH1 functionally activate essential Epstein-Barr virus major latent promoters in the Burkitt's lymphoma BJAB cell line but repress these promoters in Jurkat cells
46. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa)
47. Modulation of histone acetyltransferase activity through interaction of Epstein-Barr nuclear antigen 3C with prothymosin alpha
48. Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-mH1: A molecular link to cancer metastasis
49. An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase
50. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases
51. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals
52. Epstein-Barr virus recombinants from overlapping cosmid fragments
53. Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs
54. Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus
55. Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA
56. A first-generation packaging cell line for Epstein-Barr virus-derived vectors
57. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators